

MARKET CONSULTATION

Research Project Lifecycle Management
an IMPROVER project

Document number: 1005/FvdP

Date: September 24th 2020



Table of contents

1.	INTRODUCTION	3
2.	ASSIGNMENT	3
3.	BACKGROUND INFORMATION	4
4.	MARKET CONSULTATION PROCEDURE	5
5.	CONTACT	6
6.	TERMS AND CONDITIONS	6

1. INTRODUCTION

Prior to an upcoming European tender concerning the introduction of a Research Project Lifecycle Management solution, Radboud University Medical Center would like to consult external parties active in this domain. This consultation is intended to offer Radboud University Medical Center new insights on aspects such as, but not limited to, the number of potential suppliers, possible solutions and related future developments. That information will allow Radboud University Medical Center to enrich its requirements to be used in the beforementioned tender.

Radboud University Medical Center, founded in 1951, is a research and educational institute with an academic hospital, closely connected to Radboud University in Nijmegen. Radboud University Medical Center offers high quality specialist-level medical care. Healthcare knowledge is increased and disseminated through scientific research from molecule to man to population, education and training, thereby actively contributing to the improvement of healthcare and enhancing the well-being of people and society. Radboud University Medical Center consists of several so-called Technology Centers and 3 Research Institutes:

- Radboud Institute for Molecular Life Sciences
- Radboud Institute for Health Sciences
- The Donders Center for Medical Neuroscience

These Research Institutes cooperate and operate internationally. The ambition of Radboud University Medical Center is to play a prominent and leading role in the development of healthcare in line with its mission “To have a significant impact on healthcare”. For more information, please feel invited to have a look at: <http://www.radboudumc.nl>.

The Research Project Lifecycle Management initiative is part of a project portfolio defined within a program called IMPROVER (Informatie Management PROgramma Voor Excellente Research). This program is an enabler for a fit-for-future research domain by implementing a digital strategy for both human and non-human research within the Radboud University Medical Center. It is intended to significantly relieve researchers from an administrative burden that is embedded in today's research supporting processes and the underlying IT landscape.

2. ASSIGNMENT

Within the research domain Radboud University Medical Center is looking for a Research Project Lifecycle Management solution that facilitates collaboration between scientists and supporting departments, can guide them from ideation up until the publication of their research projects and can provide transparency for decision making purposes.

By means of this market consultation, Radboud University Medical Center would like to establish a better understanding of aspects like today's market, options that can be considered, data privacy, deployment strategies and related timelines, future market developments, lessons learned in comparable cases and indicative cost levels for such a solution.


Radboud University Medical Center would like to receive information on your company and offerings in line with the beforementioned ambition. Based on that input Radboud University Medical Center will invite a maximum of 5 companies for a presentation and possibly a demo to further expand its knowledge. Combined with all other information received, it will be used to complete and sharpen Radboud University Medical Center's requirements that will be part of the tender, foreseen to be published end 2020 / early 2021.

3. BACKGROUND INFORMATION

Research projects run through several lifecycle phases: initiation, preparation, execution, finalization and publication. In every phase multiple process steps have to be executed and different internal and external stakeholders become engaged.

Some indicative numbers:

- # scientists and supporting personnel requiring access 1,500+
- # research projects running in parallel 1,500 – 2,000



Process steps depend on the nature of the research that is done. For self-explanatory reasons, such as legislation, human research is different from non-human research. Consequently certain process steps are applicable to all types of research, some are scenario specific and other steps are optional.

Within this research domain, a project lifecycle management platform is expected to have a significant, positive impact by means of improving collaboration between scientists and supporting departments, relieving the administrative burden for researchers and others involved, and providing and easily unlocking accurate information to steer upon.

A Research Project Life Cycle Management platform will ideally enable uniform processes, simple status and progress monitoring, single data entry, one single data source, authorization management, document and version management, workflows and timely alerts. That will, directly or indirectly, lead to better cooperation, shorter project lead times, more transparency and better insights, efficiency improvements, easier and even better compliance with policies and legislation, higher quality of work, greater success, and more.

By means of this market consultation, Radboud University Medical Center would like to find the answers to the following questions regarding such a Research Project Lifecycle Management platform:

- What does today's market look like in terms of number and characteristics of potential suppliers?
- Which kind of solutions and services are available in today's market?
- How is the market expected to develop in the upcoming years?
- How can compliance to legislation, e.g. on data privacy, be guaranteed?
- Which aspects are considered key factors for a successful implementation?
- Which indicative timelines are to be included in Radboud University Medical Center's planning?
- Which indicative total cost of ownership and related benefits are to be included in Radboud University Medical Center's business case?
- How should the business partnership between the supplier and Radboud University Medical Center be shaped best?

The answers to these questions are to be included in the responses shared with Radboud University Medical Center in no more than 10 pages.

4. MARKET CONSULTATION PROCEDURE

Radboud University Medical Center is entitled to do a market consultation in order to test its line of thought, verify starting points and enrich the requirements related to the Research Project Lifecycle Management solution. It is intended to ensure that any future (European) tender is in line with the opportunities offered by the market.

Radboud University Medical Center would like to ask companies to follow the market consultation procedure as outlined below.

Description	Due date
1 Publication market consultation on www.tenderned.nl	September 24 th
2 Companies to share their interest by means of a confirmation of participation in this market consultation process	October 2 nd
3 Companies to ask questions by e-mail for clarification purposes	October 9 th
4 Radboud University Medical Center to provide answers to the questions received	October 13 th
5 Closing date submission of responses	October 16 th
6 Radboud University Center to ask questions on input received	October 19 th – 30 th

As stated, Radboud University Medical Center will invite (no more than) 5 companies to elaborate on the input that was shared and to answer questions for clarification purposes, possibly supported by a demo. Whether or not a company is invited does not indicate a qualitative assessment of the knowledge and / or experience of the company or preference from Radboud University Medical Center for a specific product or service. It is solely intended to get a better understanding of the suppliers, solutions and services in the targeted market. Below the procedure relevant for the companies invited.

Description	Date or Period
1 Radboud University Medical Center to inform companies invited for a follow-up conversation and to share the topics to be covered	November 2 nd
2 Follow-up conversations to take place based on the agenda: • Welcome • Introduction • Q&A	November 9 th – 20 th

This market consultation is not part of the tender process. Participating in this market consultation is entirely without obligation and no rights can be derived. This market consultation will not lead to any compliance issues regarding competition law, non-discrimination or transparency. The possible outcome and learnings from the market consultation will be incorporated in the documents that will be shared in the upcoming tender.

5. CONTACT

A project team has been assigned to the concerning project in which a diverse set of functions and departments is represented. As this project is part of a broad portfolio, a governance structure has been put in place for the program as a whole. Results will be therefore be shared with the IMPROVER steering committee. To ensure complete and accurate communication in a timely manner, communication on the market consultation for this project will be done via e-mail and channeled via the below mentioned single point of contact within the Radboud University Medical Center:

Name: Servé Pelsers
Function: Project Manager
E-mail: serve.pelsers@radboudumc.nl
Phone: +31 (0)6 10 61 14 24

When communicating by e-mail, please state in the subject line: "IMPROVER – Market Consultation – Research Project Lifecycle Management – [YOUR COMPANY NAME]".

6. TERMS AND CONDITIONS

By participating in the market consultation, the company declares to agree with the terms and conditions as outlined below.

- i. Radboud University Medical Center will provide its documents in English. The working language during the market consultation phase can be either English or Dutch. This also holds for supporting documents submitted.
- ii. There are no costs associated with participation by companies in this market consultation for Radboud University Medical Center.
- iii. Participating in this market consultation procedure requires a company's resources. This includes, but is not limited to, the time of the staff as well as company and / or product information.
- iv. Radboud University Medical Center assumes that the management or director(s) of the participating market party is / are in agreement with participation in this procedure.
- v. Radboud University Medical Center treats the response of companies confidentially. The information provided is only shown to employees and advisers who are directly involved in the market consultation and / or the subsequent tender, unless Radboud University Center is obliged by law to make further disclosure.
- vi. Ideas and information provided by companies can be used by Radboud University Medical Center (in the preparation of) any follow-up trajectories.
- vii. The information provided during the market consultation may differ from the information provided at a later stage for the purpose of a possible tender procedure.

- viii. The market consultation and this document cannot be regarded as an invitation to tender for any (European) tender(s) for which the market consultation serves as preparation or any other tender. Companies cannot derive any rights from participating in this market consultation.
- ix. Radboud University Medical Center reserves the right to adjust the planning of this market consultation and / or temporarily or permanently discontinue the market consultation.